Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Lung Neoplasms 3Uveal Melanoma 1Triple Negative Breast Neoplasms 1Pleural Effusion, Malignant 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 4Nivolumab 3Specimen Handling 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2utomilumab 1tislelizumab 1spartalizumab 1ruxolitinib 1pentetreotide 1niraparib 1montanide ISA 51 1fludarabine phosphate 1entinostat 1avelumab 1Valacyclovir 1Toll-Like Receptor 1 1Spinal Puncture 1Rose Bengal 1Radiosurgery 1LY2940680 1Interleukin-2 1Interleukin-13 1Injections 1Immunologic Techniques 1Fluorodeoxyglucose F18 1Cryosurgery 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Valacyclovir × Thoracic × Clear all
NCT02831933 2023-09-21

ENSIGN

The Methodist Hospital Research Institute

Phase 2 Terminated
11 enrolled 9 charts
DermatologicThoracic

Uveal Melanoma, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡